Evolus (EOLS) Other Non Operating Income (2017 - 2026)
Evolus (EOLS) posted Other Non Operating Income of $120000.0 for Q1 2026, up 1100.0% on a QoQ basis from $10000.0 in Q4 2025, and up 110.53% year-over-year from $57000.0 in Q1 2025.
Evolus (EOLS) Other Non Operating Income (2017 - 2026) Analysis & Trends
Evolus' Other Non Operating Income history runs 10 years deep, the most recent figure standing at $120000.0 for Q1 2026.
- Quarterly Other Non Operating Income rose 110.53% year-over-year to $120000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$476000.0 (down 442.45% YoY) and the FY2025 annual result came in at -$539000.0, down 524.41% from the prior year.
- Other Non Operating Income was $120000.0 for Q1 2026 at Evolus, up from $10000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $694000.0 in Q4 2023 and bottomed at -$455000.0 in Q3 2025.
- A 5-year average of $23235.3 and a median of $19000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income plunged 442.86% — and 2024, when it soared 1200.0%.
- Evolus' Other Non Operating Income stood at $84000.0 in 2022, then jumped by 726.19% to $694000.0 in 2023, then slumped by 136.46% to -$253000.0 in 2024, then jumped by 103.95% to $10000.0 in 2025, then surged by 1100.0% to $120000.0 in 2026.
- Business Quant data shows EOLS's Other Non Operating Income at $120000.0 in Q1 2026, $10000.0 in Q4 2025, and -$455000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | -455,000.00 |
| Jun 30, 2025 | -151,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Dec 31, 2024 | -253,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | 45,000.00 |
| Dec 31, 2023 | 694,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 19,000.00 |
| Mar 31, 2023 | -38,000.00 |
| Dec 31, 2022 | 84,000.00 |
| Sep 30, 2022 | -62,000.00 |
| Jun 30, 2022 | -24,000.00 |
| Mar 31, 2022 | -7,000.00 |
| Mar 31, 2021 | 971,000.00 |
| Dec 31, 2020 | -2.82 Mn |
| Mar 31, 2020 | -2.46 Mn |